SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.08-2.9%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (1301)7/3/2000 7:43:16 AM
From: Torben Noerup Nielsen  Read Replies (1) of 52153
 
Miljenko,

Do you have any idea what NBI34060 might be in addition to a non-benzodiazepene hypnotic? If it takes the best of Sonata and Ambien and leaves out the side effects and the rebound problems with Ambien, it should be quite successfull for that reason alone. There are a lot of people with low-grade sleep problems and a drug that has side effects comparable to the placebo and provides a normal nights worth of sleep should be a blockbuster.

Anyway, it now looks like the ordering should be SEPR, NBIX and then NRGN. But the impact on the stock price should be more pronounced in the case of NBIX than for SEPR due to the difference in the size of the companies.

Are there other candidates in this market? Note that there is easily room for a few competing drugs; the potential market is huge.

Thanks, Torben
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News